Literatur
Ryan CJ et al. Lancet Oncol. 2015;16(2):152–60
Parker C et al. N Engl J Med. 2013;369(3):213–23
Saad F et al. Lancet Oncol. 2016;17(9):1306–16
Smith M et al. Lancet Oncol. 2019;20(3):408–19
Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittelrichtlinie (AM-RL). BAnz AT 16.11.2018 B5
Literatur
Smith M et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(3):408–19
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schalhorn, A. Kein Vorteil durch Addition von Radium-223 zu Abirateronacetat. Info Onkol. 22, 36–37 (2019). https://doi.org/10.1007/s15004-019-6556-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15004-019-6556-3